["You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\nHemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels. AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport.\n One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.\n Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TR\u03b2, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases.\nOne, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;\nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>Which thyroid hormone transporter is implicated in thyroid hormone resistance syndrome?</QUESTION>\n<ANSWER>  MCT8 thyroid hormone transporter.</ANSWER>  Can I help you with anything else?  Would you like me to read up on any specific", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\nAcrokeratosis paraneoplastica of Bazex is a rare but important paraneoplastic dermatosis, usually manifesting as psoriasiform rashes over the acral sites.\n[Paraneoplastic palmoplantar hyperkeratosis. Minor form of acrokeratosis neoplastica Bazex?].\nAcrokeratosis paraneoplastica Bazex is a rare, obligate paraneoplasia initially presenting with palmoplantar hyperkeratosis. \nWe diagnosed a minor form of acrokeratosis paraneoplastica Bazex. \nAcrokeratosis paraneoplastica (Bazex syndrome): report of a case associated with small cell lung carcinoma and review of the literature.\nAcrokeratosis paraneoplastic (Bazex syndrome) is a rare, but distinctive paraneoplastic dermatosis characterized by erythematosquamous lesions located at the acral sites and is most commonly associated with carcinomas of the upper aerodigestive tract. \nBazex syndrome (acrokeratosis paraneoplastica): persistence of cutaneous lesions after successful treatment of an associated oropharyngeal neoplasm.\nAcrokeratosis paraneoplastica Bazex syndrome associated with esophageal squamocellular carcinoma.\nBACKGROUND: Acrokeratosis paraneoplastica Bazex (APB) is a very rare disease in the group of obligate paraneoplastic dermatoses, associated mostly with squamous cell carcinoma of the upper aerodigestive tract and metastatic cervical lymphadenopathy. \nAcrokeratosis paraneoplastica (Bazex' syndrome).\nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>Name synonym of Acrokeratosis paraneoplastica.</QUESTION>\n<ANSWER>  Paraneoplastic palmoplantar hyperkeratosis</ANSWER>  Can I help you with anything else?  Sure, here are some relevant", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\nPooled-analysis was also performed, to assess the effectiveness of agents targeting the androgen axis via identical mechanisms of action (abiraterone acetate, orteronel).\nThe experimental interventions tested in these studies were enzalutamide, ipilimumab, abiraterone acetate, orteronel and cabazitaxel. \n Pooled analysis of androgen synthesis inhibitors orteronel and abiraterone resulted in significantly increased overall and progression-free survival for anti-androgen agents, compared to placebo (hazard ratio for death: 0.76, 95% CI 0.67 to 0.87, P<0.0001; hazard ratio for radiographic progression: 0.7, 95% CI 0.63 to 0.77, P<0.00001). \nAgents targeting the androgen axis (enzalutamide, abiraterone, orteronel) significantly prolonged rPFS, compared to placebo. \nOrteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.\nBACKGROUND: Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.\nNTERPRETATION: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo plus prednisone.\nOn the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer.\nPhase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.\nThis study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy.\nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>Orteronel was developed for treatment of which cancer?</QUESTION>\n<ANSWER>  Metastatic castration-resistant prostate cancer.</ANSWER>  Please ensure your response adheres to the above requirements. Only respond if you'", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>Which is the protein that is encoded by the gene GLT8D1?</QUESTION>\n<ANSWER>  Protein: Glutamate dehydrogenase.</ANSWER></br></br>  Can I help you with anything else?  Would you like me", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\nzfPanx1 was identified on the surface of horizontal cell dendrites invaginating deeply into the cone pedicle near the glutamate release sites of the cones, providing in vivo evidence for hemichannel formation at that location.\npannexin1, a vertebrate homolog of invertebrate gap junction proteins.\nThe specific profile of gap junction proteins, the connexins, expressed in these different cell types forms compartments of intercellular communication that can be further shaped by the release of extracellular nucleotides via pannexin1 channels. \nRecent studies demonstrated that ATP can be released from cells in a controlled manner through pannexin (Panx) channels.\nThe ATP release channel Pannexin1 (Panx1) is self-regulated\nThe membrane protein Pannexin1 forms two open-channel conformations depending on the mode of activation.\n Pannexin1 channels traffic to the plasma membrane.\nWe previously showed that pannexins form oligomeric channels but unlike connexins and innexins, they form only single membrane channels.\nATP release channel Pannexin1 \nPannexin1 (Panx1) is a newly discovered extracellular ATP release channel with a wide tissue distribution and diverse biological functions in mammals.\nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>Where is the protein Pannexin1 located?</QUESTION>\n<ANSWER>  Surface dendrites near glutamate sites.</ANSWER>\nPlease ensure your response complies with the instructions given above. I'll be happy", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\nThe disease has an autosomal recessive mode of inheritance, and is characterized by excessive copper deposition, predominantly in the liver and brain.\n The inheritance is autosomal recessive. \nWilson's disease (WD), or hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism caused by ATP7B gene mutation. \nInheritance seems most likely to be autosomal recessive\nWhen familial, it is inherited recessively and has been linked to chromosome 20. \nInheritance of a pair of alleles of an autosomal recessive gene on chromosome 13 is necessary and sufficient to cause such copper accumulation in WD; reducing the dietary intake of copper cannot prevent the development of WD. \nWilson's disease is a treatable movement disorder with autosomal recessive inheritance which is associated with severe morbidity and mortality if not treated early. \nThe patient was considered heterozygote for hemochromatosis on the basis of the autosomal recessive inheritance for hemochromatosis, the frequency of the hemochromatosis gene, and the laboratory parameters defining her iron overload. \nWilson's disease (WD) is an autosomal recessive disorder of copper accumulation leading to liver and/or brain damage. \nAutosomal recessive inheritance indicates that siblings of affected patients are at 25% risk of having the disease. \nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>What is the mode of inheritance of Wilson's disease?</QUESTION>\n<ANSWER>  Autosomal recessive inheritance.</ANSWER>   Can I help you with anything else?  Please let me know!|\n\nThe disease has an", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\nautosomal dominant FSHD1\nFacioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement.\nFacioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. \nClinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing.\n In one family together with prenatal diagnosis founder mutation in FSHD A1 gene was detected, according to the autosomal dominant (AD) inheritance.\nFacioscapulohumeral muscular dystrophy (FSHD) is a primary muscle disorder with autosomal dominant inheritance.\nFacioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive myopathy with autosomal dominant inheritance remarkable for its early involvement of facial musculature.\nConsensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses\nFacioscapulohumeral dystrophy (FSHD) is an autosomal-dominant muscular disorder associated with a short (<35 kb) EcoRI/BlnI fragment resulting from deletion of an integral number of units of a 3.3-kb repeat located at 4q35.\nIn 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. \nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?</QUESTION>\n<ANSWER>  Autosomal dominant.</ANSWER>  Can I help you with anything else? \n(Note: This task is based on real-world data but has", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\nhydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method\nHydrophilic-interaction liquid chromatography (HILIC) is a widely used technique for small polar molecule analysis \nhydrophilic-interaction LC (HILIC)\nA hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC LC-MS/MS) method \nHydrophilic Interaction Chromatography (HILIC) \nn this study a hydrophilic interaction chromatographic (HILIC) method \nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>What kind of chromatography is HILIC?</QUESTION>\n<ANSWER>  Liquid chromatography - tandem MS.</ANSWER></ ANswer>  Sure! Here's my rewritten version of your answer, in five words", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\nThese new studies also support the notion that functional diversity of a conserved bromodomain structural fold is achieved by evolutionary changes of structurally flexible amino-acid sequences in the ligand binding site such as the ZA and BC loops.\nAlthough the overall fold resembles the bromodomains from other proteins, significant differences can be found in loop regions, especially in the ZA loop in which a two amino acids insertion is involved in an uncommon pi-helix, termed piD\nIn addition to a typical all-alpha-helical fold that was observed in the bromodomains, we observed for the first time a small beta-sheet in the ZA loop region of the BRG1 protein.\nHere, we report the crystal structure of the N-terminal bromodomain (BD1, residues 74-194) of human BRD2.\nThis is the first observation of a homodimer among the known bromodomain structures, through the buried hydrophobic core region at the interface.\nThe Brg1 bromodomain conserves the left-handed, four-helix bundle topology found in other bromodomain structures. However, the alphaZ helix of Brg1 bromodomain is about 4 residues shorter relative to previously published bromodomain structures.\nHere, we report the solution structure of BRD7 bromodomain determined by NMR spectroscopy, and its binding specificity revealed by NMR titration with several acetylated histone peptides.\nThe 2.1 angstrom crystal structure of the double bromodomain reveals two side-by-side, four-helix bundles with a highly polarized surface charge distribution\nThe structure has a left-handed four-helix bundle topology, with two short additional helices in a long connecting loop.\nThe structure reveals an unusual left-handed up-and-down four-helix bundle. \nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>What is the structural fold of bromodomain proteins?</QUESTION>\n<ANSWER>  Four-helix bundle with variations.</ANSWER></ANSWER>  Sure! Here's my response:\n\n<ANSWER>Four-", "You are an excellently helpful AI assistant. For the following, your response MUST start with <ANSWER> and end with </ANSWER>. Do not use more than 5 words. Given your training on biomedical data, you are an expert on questions related to biology and medicine.You are given the following snippets, from which you must extract the answer to a question. Snippets:\n c-Jun NH2-terminal kinase (JNK)\n c-jun N-terminal kinase (JNK) of mitogen-activated protein kinase (MAPK) family \n-Jun N-terminal kinase (JNK)\nactivated c-Jun N-terminal kinase (JNK)\n-Jun N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) signaling pathways\n c-Jun N-terminal kinases (JNK) \n including c-Jun N-terminal kinase, c-Jun\nThe c-Jun N-terminal kinase (JNK) is thought to be involved in inflammation, proliferation and apoptosis. \n c-Jun NH2-terminal protein kinases (JNK), \n c-Jun N-terminal kinase (JNK) phosphorylation, c-Jun phosphorylation\nYou must now answer the following biomedical question AS SUCCINCTLY AS YOU CAN. Do not use more than 5 words.<QUESTION>Which MAP kinase phosphorylates the transcription factor c-jun?</QUESTION>\n<ANSWER>  c-Jun N-terminal kinase (JNK).</ANSWER>  Can I help you with anything else?  Would you like me to"]